Efficacy of short-term interferon therapy for patients infected with hepatitis C virus genotype 2a

American Journal of Gastroenterology

Volumn 100, Issue 4, 2005, Pages 862-867

  Tabaru, Akinari ^a   Narita, Ryoichi ^a   Hiura, Masaaki ^a   Abe, Shintaro ^a   Otsuki, Makoto ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA; ALPHA2B INTERFERON; ANTIVIRUS AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INTERSTITIAL PNEUMONIA; LIVER FUNCTION TEST; MALAISE; MALE; MONOTHERAPY; PATIENT MONITORING; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RNA ANALYSIS; SHORT COURSE THERAPY; TREATMENT OUTCOME; VERTIGO; VIRUS LOAD; BLOOD; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECT; GENETICS; INTRAMUSCULAR DRUG ADMINISTRATION; LONG TERM CARE; MIDDLE AGED; PROSPECTIVE STUDY; VIROLOGY;

ADULT; ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON ALFA-2B; LIVER FUNCTION TESTS; LONG-TERM CARE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 17544375064     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2005.40826.x     Document Type: Article

References (26)

1. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology 1990;12:671-5.
2. Tin F, Magrin S, Crax A, et al. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomized clinical trials. J Hepatol 1991;13:192-9.
3. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis: Effects of dose and duration. Hepatology 1996;24:778-89.
4. Camm C, Giunta M, Linea C, et al. The effect of interferon on the liver in chronic hepatitis C: A quantitative evaluation of histology by meta-analysis. J Hepatol 1997;26:1187-99.
5. Camm C, Giunta M, Pinzello G, et al. Chronic hepatitis C and interferon alpha: Conventional and cumulative meta-analyses of randomized controlled trial. Am J Gastroenterol 1999;94:581-95.
6. Hoofnagle JH, Di Bisceglie AM, et al. Antiviral therapy of hepatitis C - Present and future. J Hepatol 1993;17:S130-6.
7. Simmonds P. Variability of hepatitis C virus. Hepatology 1995;21:570-83.
8. Yoshioka K, Kakumu S, Wakita T, et al. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-(therapy: Relationship to genotypes of hepatitis C virus. Hepatology 1992;16:293-9.
9. Matsumoto A, Tanaka E, Suzuki T, et al. Viral and host factors that contribute to efficacy of interferon-(2a therapy in patients with chronic hepatitis C. Dig Dis Sci 1994;39:1273-1280.
10. Shiratori Y, Kato N, Yokosuka O, et al. Predictors of the efficacy of interferon therapy in chronic hepatitis C virus infection. Gastroenterology 1997;113:558-66.
11. Tabaru A, Ono M, Narita R, et al. A short period of interferon therapy led to a sustained response in two cases of chronic hepatitis C. J Gastroenterol Hepatol 2002;16:947-8.
12. Desmet VJ, Gerber M, Hoofnagle JH, et al. Classification of chronic hepatitis: Diagnosis, grading and staging. Hepatology 1994;19:1513-20.
13. Okamoto H, Mishiro S, Tokita H, et al. Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a. Hepatology 1994;20:1131-6.
14. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994;19:1321-4.
15. Di Bisceglie AM, Hoofnagle JH. Optimal therapy of hepatitis C. Hepatology 2002;36:S121-7.
16. Management of hepatitis C: 2002. NIH Consensus Development Conference Statement. Hepatology 2002;36:S3-15.
17. Okanoue T, Sakamoto S, Itoh Y, et al. Side effect of high dose interferon therapy for chronic hepatitis C. J Hepatol 1996;25:283-91.
18. Hakozaki Y, Shirahama T, Katou M, et al. A controlled study to determine the optimal dose regimen of interferon alfa-2b in chronic hepatitis C. Am J Gastroenterol 1995;90:1246-9.
19. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavitin for the initial treatment of chronic hepatitis C. Semin Liver Dis 1999;19:57-65.
20. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomized trial. Lancet 2001;358:958-65.
21. Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
22. Iino S, Hino K, Kuroki T, et al. Treatment of chronic hepatitis C with high-dose interferon alfa-2b. A multicenter study. Dig Dis Sci 1993;38:612-8.
23. Nakamura H, Ito H, Kimura Y, et al. The importance of initial daily administration of interferon alpha for the eradication of hepatitis C virus in patients with chronic hepatitis C: A multicenter randomized trial. Hepatogastroenterology 1998;45:1045-55.
24. Kjaergard LL, Krogsgaard K, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: Systematic review of randomised trials. Br Med J 2001;323:1151-5.
25. Diago M, Surez D, Garcia-Villarreal L, et al. Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis C. J Med Virol 2001;64:460-5.
26. Gonzalez HJ, Ho SB, Gross JB, et al. Efficacy of daily induction dosing vs standard thrice weekly dosing of interferon-alpha2B for initial treatment of chronic hepatitis C. Dig Dis Sci 2002;47:784-92.